drug development

R&D
8th Annual Antifibrotic Drug Development Summart
Partner Content

8th Annual Antifibrotic Drug Development Summit

The landmark FDA approval of the first MASH therapeutic, the orphan drug designation for systemic sclerosis trials, and the rapid advancement of IPF treatments through clinical phases have ignited